Christian Marth
High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome
Wolf D, Reimer D, Hartmann G, Sopper S, Sprung S, Marth C, Wieser V, Zeimet A, Fiegl H, Bösch M. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. Int J Cancer 2019
Dec 4, 2019High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome
Dec 4, 2019Int J Cancer 2019
Wolf Dominik, Reimer Daniel, Hartmann Gunther, Sopper Sieghart, Sprung Susanne, Marth Christian, Wieser Verena, Zeimet Alain G, Fiegl Heidi, Bösch Maximilian
Ovarian Cancer Stem Cell Heterogeneity
Hatina J, Bösch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet A. Ovarian Cancer Stem Cell Heterogeneity. Adv Exp Med Biol 2019; 1139:201-221.
Jan 1, 2019Ovarian Cancer Stem Cell Heterogeneity
Jan 1, 2019Adv Exp Med Biol 2019; 1139:201-221
Hatina Jiri, Bösch Maximilian, Sopper Sieghart, Kripnerova Michaela, Wolf Dominik, Reimer Daniel, Marth Christian, Zeimet Alain G
Evaluation of Vav3.1 as prognostic marker in endometrial cancer
Bösch M, Reimer D, Wolf D, Hatina J, Rössler J, Wiedemair A, Fiegl H, Marth C, Sopper S, Zeimet A. Evaluation of Vav3.1 as prognostic marker in endometrial cancer. J Cancer Res Clin Oncol 2018; 144:2067-2076.
Aug 6, 2018Evaluation of Vav3.1 as prognostic marker in endometrial cancer
Aug 6, 2018J Cancer Res Clin Oncol 2018; 144:2067-2076
Bösch Maximilian, Reimer Daniel, Wolf Dominik, Hatina Jiri, Rössler Julia, Wiedemair Annemarie, Fiegl Heidi, Marth Christian, Sopper Sieghart, Zeimet Alain G
Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response
Reimer D, Hackl H, Parson W, Altevogt P, Hatina J, Sopper S, Marth C, Wolf D, Bösch M, Zeimet A. Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response. Int J Cancer 2017; 142:1640-1651.
Dec 14, 2017Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response
Dec 14, 2017Int J Cancer 2017; 142:1640-1651
Reimer Daniel, Hackl Hubert, Parson Walther, Altevogt Peter, Hatina Jiri, Sopper Sieghart, Marth Christian, Wolf Dominik, Bösch Maximilian, Zeimet Alain G
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 19:127-138.
Nov 17, 2017Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Nov 17, 2017Lancet Oncol 2017; 19:127-138
Colleoni Marco, Di Lauro Vincenzo, Gombos Andrea, Ruhstaller Thomas, Burstein Harold, Ribi Karin, Bernhard Jürg, Viale Giuseppe, Maibach Rudolf, Rabaglio-Poretti Manuela, Gelber Richard D, Coates Alan S, Di Leo Angelo, Regan Meredith M, Goldhirsch Aron, O'Reilly Seamus, Müller Bettina, Marth Christian, Luo Weixiu, Karlsson Per, Chirgwin Jacquie, Aebi Stefan, Jerusalem Guy, Neven Patrick, Hitre Erika, Graas Marie-Pascale, Simoncini Edda, Kamby Claus, Thompson Alastair, Loibl Sibylle, Gavilá Joaquín, Kuroi Katsumasa, SOLE Investigators